CRISPR-based KCC2 upregulation attenuates drug-resistant seizure in mouse models of epilepsy.
Jiaying ShiHuhu XinYuying ShaoSijie DaiNa TanZhisheng LiFan FeiDi WuYi WangYuan PingZhong ChenPublished in: Annals of neurology (2023)
These results demonstrated the translational potential of AAV-mediated delivery of CRISPRa for treating neurological disorders by modulating abnormal gene expression that is directly associated with neuronal excitability, validating KCC2 as a promising therapeutic target for treating drug-resistant epilepsy. This article is protected by copyright. All rights reserved.
Keyphrases
- drug resistant
- gene expression
- multidrug resistant
- acinetobacter baumannii
- temporal lobe epilepsy
- mouse model
- signaling pathway
- crispr cas
- dna methylation
- genome wide
- cerebral ischemia
- poor prognosis
- cell proliferation
- genome editing
- transcranial direct current stimulation
- human health
- climate change
- long non coding rna
- pseudomonas aeruginosa